<DOC>
	<DOCNO>NCT00258856</DOCNO>
	<brief_summary>The study design evaluate persistence bactericidal antibodies subject age 7 15 year ( yet 16 year ) vaccinate five year previously Study 603-02 . In addition , kinetics antibody response evaluate subset participant receive booster dose Menactra® vaccine child age group previously vaccinate meningococcal vaccine meningitis disease receive dose Menactra® vaccine .</brief_summary>
	<brief_title>Persistence Antibodies Children Aged 7 15 Years Who Previously Received One Dose Menactra® Menomune®</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subject healthy , determined medical history . Subject age 7 15 year ( yet 16 year ) . For subject participate Study 60302 , subject previously receive one dose Menactra® vaccine Menomune®A/C/Y/W135 vaccine . The date vaccination Study 60302 occur 5 year ± 6 month collection blood sample obtain Study MTA23 . A negative urine pregnancy test require menstruate female subject . Parent/legal guardian sign Institutional Review Board ( IRB ) approve informed consent form subject sign IRBapproved assent form . Subjects participate sanofi pasteur Study MTA17 Stage I ( subset subject Study 60302 recruit followup challenge study ) History document invasive meningococcal disease Received meningococcal vaccine Received vaccine 28day period prior enrollment Received antibiotic therapy within 72 hour prior collection blood sample Actively enrol schedule enrol another clinical study Serious chronic disease ( i.e. , cardiac , renal , neurologic , rheumatologic , metabolic , gastrointestinal , psychiatric , organ system ) Known suspect impairment immunologic function Acute medical illness without fever within 72 hour oral temperature ≥ 100.4°F ( ≥ 38.0°C ) time inclusion Scheduled receive vaccination 7day 14day period enrollment Administration immune globulin , blood product , corticosteroid within 8 week ( 56 day ) study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Personal family history GuillainBarres Syndrome Suspected known hypersensitivity vaccine component Unavailable entire study period unable attend schedule visit comply study procedure Any condition , opinion investigator , would pose health risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal infection</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
</DOC>